Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gernot Marx

Showing results (271-280 of 291) with videos related to

Pageof 30
Sort By:
Journal of Intensive Care|April 2, 2016
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failureAlexandre Mebazaa, Pierre François Laterre, James A Russell, et al.
Kidney International Reports|November 20, 2018
Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) StudyAlexa Hollinger, Xavier Wittebole, Bruno François, et al.
Intensive Care Medicine|October 4, 2021
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre-François Laterre, Peter Pickkers, Gernot Marx, et al.
JAMA|October 4, 2016
Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical TrialDidier Keh, Evelyn Trips, Gernot Marx, et al.
JAMA|June 14, 2012
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trialFrank M Brunkhorst, Michael Oppert, Gernot Marx, et al.
Infection|August 20, 2021
Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Frontiers in Immunology|January 2, 2023
Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofilingFelix Schreibing, Monica T Hannani, Hyojin Kim, et al.
Infection|July 6, 2021
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Critical Care (London, England)|December 26, 2018
Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) studyAlexandre Mebazaa, Christopher Geven, Alexa Hollinger, et al.
JAMA Internal Medicine|July 19, 2016
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical TrialFrank Bloos, Evelyn Trips, Axel Nierhaus, et al.
Pageof 30

Showing results (271-280 of 291) with videos related to

Sort By:
Pageof 30
Journal of Intensive Care|April 2, 2016
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failureAlexandre Mebazaa, Pierre François Laterre, James A Russell, et al.
Kidney International Reports|November 20, 2018
Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) StudyAlexa Hollinger, Xavier Wittebole, Bruno François, et al.
Intensive Care Medicine|October 4, 2021
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre-François Laterre, Peter Pickkers, Gernot Marx, et al.
JAMA|October 4, 2016
Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical TrialDidier Keh, Evelyn Trips, Gernot Marx, et al.
JAMA|June 14, 2012
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trialFrank M Brunkhorst, Michael Oppert, Gernot Marx, et al.
Infection|August 20, 2021
Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Frontiers in Immunology|January 2, 2023
Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofilingFelix Schreibing, Monica T Hannani, Hyojin Kim, et al.
Infection|July 6, 2021
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)Jakob J Malin, Christoph D Spinner, Uwe Janssens, et al.
Critical Care (London, England)|December 26, 2018
Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) studyAlexandre Mebazaa, Christopher Geven, Alexa Hollinger, et al.
JAMA Internal Medicine|July 19, 2016
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical TrialFrank Bloos, Evelyn Trips, Axel Nierhaus, et al.
Pageof 30